Analyst firms · J.P. Morgan · KPTI
J.P. Morgan KPTI price target and rating history
Karyopharm Therapeutics Inc. (KPTI) · Health Care
J.P. Morgan rates Karyopharm Therapeutics Inc. (KPTI) Neutral with a $8 price target, as of its latest action on Feb 9, 2022. It has published 3 rating actions on KPTI since August 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a KPTI price target in the last 12 months, the median target is $3.
- Current rating
- Neutral
- Price target
- $8
- Median target, all firms
- $3
- Actions on KPTI
- 3
Every J.P. Morgan rating on KPTI
- Feb 9, 2022
- Aug 6, 2021
- Aug 6, 2021
How other firms rate KPTI
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | $3 | Jul 31, 2026 |
| Robert W. Baird | Neutral | $3 | Jul 31, 2026 |
| Rodman & Renshaw | Buy | $28 | Mar 10, 2026 |
| Cantor Fitzgerald | Overweight | Feb 5, 2026 |
Questions about J.P. Morgan and KPTI
- What is J.P. Morgan's price target for KPTI?
- J.P. Morgan's latest stated price target for Karyopharm Therapeutics Inc. (KPTI) is $8, from its action on Feb 9, 2022.
- What is J.P. Morgan's rating on KPTI?
- J.P. Morgan rates KPTI Neutral, a neutral rating, as of Feb 9, 2022.
- When did J.P. Morgan last change its view on KPTI?
- On Feb 9, 2022, J.P. Morgan upgrades to Neutral from Underweight, price target $8.
- How does J.P. Morgan's KPTI target compare with other analysts?
- Across 3 firms with a KPTI price target in the last 12 months, the median target is $3.
More KPTI rating histories
All J.P. Morgan ratingsKPTI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.